MARKET

BGNE

BGNE

Beigene Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

137.32
+5.65
+4.29%
After Hours: 137.32 0 0.00% 16:31 05/20 EDT
OPEN
139.00
PREV CLOSE
131.67
HIGH
139.45
LOW
129.30
VOLUME
259.74K
TURNOVER
0
52 WEEK HIGH
426.56
52 WEEK LOW
120.00
MARKET CAP
14.10B
P/E (TTM)
-9.0554
1D
5D
1M
3M
1Y
5Y
BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, May 17, 2022--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, yesterday announced the opening ...
Business Wire · 5d ago
BeiGene to Open Regional Office in Switzerland
MT Newswires · 5d ago
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The company’s loss tripled last year on growing competition for its core product, wh...
Benzinga · 05/13 15:55
BRIEF-Beigene Says Q1 Net Loss 2.9 Billion Yuan
reuters.com · 05/13 09:07
MSCI to reshuffle stock indexes after quarterly review
reuters.com · 05/12 21:19
BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress
CAMBRIDGE, Mass., BEIJING & BASEL, Switzerland, May 12, 2022--BeiGene announced 20 presentations from the Company’s global clinical development programs in hematologic malignancies at EHA.
Business Wire · 05/12 14:00
52 Stocks Moving In Wednesday's Mid-Day Session
Gainers Trecora Resources (NYSE: TREC) shares jumped 26.6% to $9.56 as the company agreed to be acquired by an affiliate of Balmoral Funds at $9.81 per share in cash or an enterprise value of $247 million.
Benzinga · 05/11 16:25
Why Roche's Flop In Lung Cancer Hammered Arcus, Iteos And Others
A Roche failure in lung cancer sent a ripple through biotech stocks on Wednesday, toppling Arcus, BeiGene, Iteos and others.
Investor's Business Daily · 05/11 13:47
More
No Data
Learn about the latest financial forecast of BGNE. Analyze the recent business situations of Beigene Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

11.76%Strong Buy
70.59%Buy
17.65%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BGNE stock price target is 322.41 with a high estimate of 470.00 and a low estimate of 177.00.
High470.00
Average322.41
Low177.00
Current 137.32
EPS
Actual
Estimate
-4.93-3.70-2.46-1.23
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 335
Institutional Holdings: 67.61M
% Owned: 65.83%
Shares Outstanding: 102.71M
TypeInstitutionsShares
Increased
92
2.16M
New
21
174.54K
Decreased
76
2.14M
Sold Out
38
258.61K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.64%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Executive Director
John Oyler
President/Chief Operating Officer/General Manager
Xiaobin Wu
Co-Founder/Non-Executive Director
Xiaodong Wang
Chief Financial Officer
Julia Wang
Other
Jane Huang
Other
Mark Lanasa
Secretary
Hing Ling Chau
Non-Executive Director
Anthony Hooper
Non-Executive Independent Director
Timothy Chen
Non-Executive Independent Director
Han Dugan
Non-Executive Independent Director
Donald Glazer
Non-Executive Independent Director
Michael Goller
Non-Executive Independent Director
Ranjeev Krishana
Non-Executive Independent Director
Thomas Malley
Non-Executive Independent Director
Alessandro Riva
Non-Executive Independent Director
Corazon Sanders
Non-Executive Independent Director
Qingqing Yi
No Data
No Data
About BGNE
Beigene Ltd is a biotechnology company in the commercial stage. The Company focuses on research and development (R&D), production and commercialization of innovative drugs. The Company has three products approved for listing, including Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290). The Company also has eight products in clinical stage, including BGB-283, BGB-A333, BGB-A425, BGB-A1217, BGB-A445, BGB-11417, BGB-10188 and BGB-15025. The Company's business covers China, the United States, Australia, Canada, Singapore, Russia, Brazil, Europe and other countries and regions.

Webull offers kinds of Beigene Ltd (ADR) stock information, including NASDAQ:BGNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BGNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BGNE stock methods without spending real money on the virtual paper trading platform.